TROP-2–directed antibody–drug conjugate delivering SN-38 (topoisomerase I inhibitor).
Humanized anti-TROP2 monoclonal antibody linked to SN-38 (active metabolite of irinotecan). After binding TROP2 on tumor cells and internalization, the linker is cleaved to release SN-38, which inhibits topoisomerase I by stabilizing the Topo I–DNA complex, leading to DNA damage, replication arrest, and apoptosis (with potential bystander effect).
NO
INDIRECT
Sacituzumab govitecan targets TROP2 on tumor cells; after internalization it releases SN-38, which inhibits topoisomerase I in those TROP2+ cells, causing DNA damage and apoptosis (with possible bystander effect).
A bispecific T-cell engager (BiTE) antibody that binds CD19 on B cells and CD3 on T cells to redirect cytotoxic T cells against CD19+ B cells and modulate aberrant humoral immunity.
A single‑chain bispecific antibody that binds CD19 on B cells and CD3 on T cells, forming an immunologic synapse that activates cytotoxic T cells to release perforin/granzymes and lyse CD19+ B cells, resulting in B‑cell depletion and modulation of humoral immunity.
NO
INDIRECT
Blinatumomab binds CD3ε on T cells to activate and redirect them to kill CD19+ B cells via perforin/granzyme release; CD3ε-expressing T cells are effectors, not targets.
TROP-2–directed antibody–drug conjugate with a topoisomerase I payload.
TROP-2–targeting humanized IgG1 ADC; after binding and internalization, pH/enzymatic cleavage of the linker releases the topoisomerase I inhibitor tirumotecan, inhibiting DNA replication and causing cell-cycle arrest and apoptosis, with a bystander killing effect.
YES
DIRECT
The ADC binds TROP-2 on target cells, is internalized, and linker cleavage releases the topoisomerase I inhibitor tirumotecan, inhibiting DNA replication and inducing cell-cycle arrest and apoptosis (with a bystander effect).
TROP-2–directed antibody–drug conjugate with a topoisomerase I payload.
TROP-2–targeting humanized IgG1 ADC; after binding and internalization, pH/enzymatic cleavage of the linker releases the topoisomerase I inhibitor tirumotecan, inhibiting DNA replication and causing cell-cycle arrest and apoptosis, with a bystander killing effect.
NO
INDIRECT
Cells are not targeted via DNA topoisomerase I expression. The ADC binds TROP-2, is internalized, and releases tirumotecan, which inhibits TOP1 to block DNA replication and induce apoptosis; a bystander effect may occur.
Investigational TROP-2–directed antibody–drug conjugate with a topoisomerase I payload.
TROP‑2–targeted monoclonal antibody delivers a topoisomerase I inhibitor payload to TROP‑2–expressing tumor cells. After binding and internalization, linker cleavage releases the topo I inhibitor, causing DNA damage (single‑strand breaks) and tumor cell death, with potential bystander effect depending on linker permeability.
YES
DIRECT
An anti–TROP-2 antibody–drug conjugate binds TROP-2 on tumor cells, is internalized, and releases a topoisomerase I inhibitor that induces DNA damage (single-strand breaks) leading to cell death; membrane-permeable payload can cause bystander killing.